To improve our understanding of the frequency and diversity of PI3K-AKT-mTOR pathway genetic aberrations in prostate cancer, we used the cBioPortal platform to survey three publicly available prostate cancer genomic datasets with primary and/or metastatic patient samples for a panel of 68 genes that encode key PI3K cascade components/effectors [47,48]. This evidence concerns the gene PIK3CG and prostate carcinoma.